Obesity Drugs: Stocks to Watch
George Budwell, The Motley Fool - Motley Fool - Tue Jun 09, 10:06AM CDT
Obesity is a big healthcare problem. In the U.S. alone, an estimated 35% of adults, or 85 million people, are believed to be obese, putting them at increased risk of certain forms of cancer, cardiovascular disease, and type 2 diabetes, among many...
OREX: 2.53 (+0.15), ARNA: 2.19 (+0.14)
Asco - A Sirius Lead For Daratumumab
EP Vantage - at Seeking Alpha - Mon Jun 01, 12:16PM CDT
G enmab ( OTCPK:GMXAY , OTC:GNMSF investors celebrated earlier this month when Johnson & Johnson (NYSE: JNJ ) said it would file its partnered multiple myeloma project daratumumab this year based on the phase II Sirius study. Recently...
JNJ: 95.37 (+0.29), CELG: 117.38 (-0.59)
Synergy: This Popular Biotech Is Approaching A Major Clinical Event, Here's How To Trade It
Lowenthal Capital Partners - at Seeking Alpha - Sat May 30, 12:05PM CDT
SGYP: 6.32 (+0.18), IRWD: 11.36 (+0.24)
Orexigen Therapeutics, Inc. Goes From Biotech Beauty to Dreadful Drugmaker
Brian Orelli, The Motley Fool - Motley Fool - Sat May 16, 10:04AM CDT
Orexigen Therapeutics has been the darling of the obesity drugmakers, doing something Arena Pharmaceuticals and VIVUS weren't able to do: keep its share price above where it was when its weight-loss drug was approved in September. ...
OREX: 2.53 (+0.15), VVUS: 2.00 (unch), ARNA: 2.19 (+0.14)
Seeking Alpha's Biotech Weekly: Orexigen's Wreck, Stagnant Gilead, And More
SA Editor Mike Taylor - Seeking Alpha - Fri May 15, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors weighed the options for Orexigen (NASDAQ: OREX ) after the...
PRGO: 160.60 (+2.26), VRTX: 110.00 (+0.97), OVAS: 12.25 (+1.00), MYL: 42.55 (-0.12), AMGN: 149.59 (-0.31), GSK: 40.22 (+0.06), ALR: 47.03 (-0.26), ONTY: 2.88 (+0.08), CELG: 117.38 (-0.59), PVCT: 0.56 (unch), JNJ: 95.37 (+0.29), OREX: 2.53 (+0.15), FCSC: 4.18 (+0.31), NVIV: 8.81 (+0.47), GILD: 100.65 (-0.16), GWPH: 87.75 (+0.45), CTSO: 6.27 (-0.08), ACHN: 7.57 (-0.10), RMD: 54.30 (+0.39), SNY: 48.75 (+0.03), PBYI: 79.41 (+3.89)
Dendrimers Coming Of Age: Starpharma's Star Is Rising
Keith Williams - at Seeking Alpha - Fri May 15, 11:05AM CDT
PFE: 33.24 (+0.15), AZN: 32.23 (-0.16), LLY: 86.14 (+2.37), SNY: 48.75 (+0.03)
How Not To Handle Your Clinical Data
Derek Lowe - Seeking Alpha - Wed May 13, 11:59AM CDT
We turn now to Orexigen (NASDAQ: OREX ), one of the small companies trying to make headway in the obesity market. Earlier this year, a patent application from them published, claiming that their drug ( Contrave , a sustained release formulation...
OREX: 2.53 (+0.15)
Takeda - Orexigen partnership on the rocks after CV outcomes study halted
Seeking Alpha - at Seeking Alpha - Wed May 13, 6:25AM CDT
OREX: 2.53 (+0.15)
First patient dosed in Takeda's Phase 3 study of proteasome inhibitor in myeloma
Seeking Alpha - at Seeking Alpha - Tue May 12, 6:31AM CDT
Infinity Pharmaceuticals: Analyzing The Impact Of Repurchasing Takeda's Royalty Agreement
Jonathan Liu - at Seeking Alpha - Mon Apr 13, 7:50PM CDT
INFI: 8.37 (+0.48), ABBV: 55.64 (-0.40)
Takeda Pharma offers $2.2B to settle Actos cases
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 6:31AM CDT
LLY: 86.14 (+2.37)
Infinity Pharma buys out royalty obligations from Takeda for $52.5M
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 10:30AM CDT
ABBV: 55.64 (-0.40), INFI: 8.37 (+0.48)
Why ImmunoGen Inc. is Soaring Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 23, 2:25PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. ImmunoGen, What's happening: Shares in ...
IMGN: 10.91 (+0.25), AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37)
Takeda licenses ImmunoGen's ADC technology to develop cancer therapeutics
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 6:47AM CDT
IMGN: 10.91 (+0.25)
Orexigen torpedoes shorts on news of Contrave's heart safety benefit
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 12:03PM CST
OREX: 2.53 (+0.15), VVUS: 2.00 (unch), ARNA: 2.19 (+0.14)
Amgen's Kyprolis beats Takeda's Velcade in head-to-head study
Seeking Alpha - at Seeking Alpha - Sun Mar 01, 10:53PM CST
AMGN: 149.59 (-0.31)
Heptares Takes Sosei Out Of Its Comfort Zone
EP Vantage - Seeking Alpha - Mon Feb 23, 2:37PM CST
It makes perfect sense for a small Japanese company to harbour expansion plans, but the private UK neuroscience player Heptares Therapeutics makes an unusual bedfellow for Sosei ( OTC:SOLTF ) , a group with a predominantly respiratory focus....
AZN: 32.23 (-0.16), NVS: 91.90 (-0.71)
Interim results positive for Takeda blood cancer med
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 6:17AM CST
Canada accepts Sucampo's NDS for constipation med
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 6:38AM CST
SCMP: 18.19 (-1.21)
AMAG and Takeda part ways on ferumoxytol
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 7:31AM CST
AMAG: 40.06 (+1.32)